Algiers, November 28, 2025 – A landmark agreement, the “Algiers Declaration,” has been adopted by participants at the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies. This declaration aims to serve as a common ground for bolstering the continent’s health sovereignty by unifying efforts to develop the African pharmaceutical industry and reduce reliance on imports.
The declaration is the culmination of two days of discussions between ministers of health and pharmaceutical industries, as well as representatives from African and international bodies. The conference, held at the Abdellatif Rahal International Conference Center in Algiers, took place under the high patronage of the President of Algeria, Abdelmadjid Tebboune.
The “Algiers Declaration,” read by the Minister of Pharmaceutical Industry, Wassim Kouideri, was adopted by 29 participating nations. These countries include Algeria, South Africa, Angola, Benin, Botswana, Burkina Faso, Cameroon, Congo, Democratic Republic of Congo, Djibouti, Egypt, Ethiopia, Gabon, Ghana, Ivory Coast, Kenya, Madagascar, Mozambique, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, Tanzania, Chad, Togo, Uganda, Zambia, and Zimbabwe.
The declaration outlines 13 collective commitments for participating African nations, embodying a unified vision for achieving health security on the continent. These commitments include strengthening pharmaceutical and vaccine manufacturing hubs at local and regional levels across Africa, leveraging opportunities offered by the African Continental Free Trade Area (AfCFTA), and encouraging sustainable public-private partnerships to increase industrial capacity and stimulate long-term investments.
Furthermore, participating African countries commit to strengthening national regulatory agencies and accelerating regulatory harmonization through the African Medicines Agency and the African Medicines Regulatory Harmonization program. This aims to ensure the quality, safety, and efficacy of health products. Institutional development plans to reach at least Maturity Level 3 of regulatory maturity levels will contribute to achieving this goal.
The “Algiers Declaration” also includes support for the mutual recognition of regulatory decisions within regional groupings to facilitate faster access to quality medicines, vaccines, and medical devices, supporting domestic pharmaceutical production.
